Investors Can Lead Class Action Against Capricor Therapeutics for Securities Fraud

Capricor Therapeutics Faces Securities Fraud Class Action

In an important development for investors, the Schall Law Firm has announced the opportunity for shareholders of Capricor Therapeutics, Inc. to lead a class action lawsuit against the company. This lawsuit is grounded in allegations of violations of the Securities Exchange Act, specifically Sections 10(b) and 20(a), alongside Rule 10b-5.

Background of the Case

Capricor Therapeutics, listed on NASDAQ under the symbol CAPR, has come under scrutiny for its alleged misleading statements relating to its drug candidate, deramiocel. Between October 9, 2024, and July 10, 2025, the public statements made by Capricor are being challenged. Investors who purchased the company’s securities during this period are encouraged to get in touch with the Schall Law Firm by September 15, 2025, if they suffered financial losses as a result.

Allegations Against Capricor

The heart of the allegations is that Capricor provided false and misleading information to the market. While they promoted encouraging updates regarding the advancement toward FDA approval for deramiocel, internal communications suggest that critical adverse data from the Phase 2 HOPE-2 trial were concealed. This disconnect between public proclamations and internal realities has left many investors feeling deceived.

Call to Investors

Investors who believe they have been affected by these actions are invited to consider joining the class action. Contact can be made through Brian Schall of the Schall Law Firm at their office in Los Angeles, where they can discuss their rights at no charge. Although the class has yet to be certified, potential participants are cautioned that if they choose to take no action, they will remain absent from the legal proceedings.

This class action represents a significant opportunity for harmed shareholders to recover losses stemming from the alleged securities fraud. The Schall Law Firm has a reputation for representing global investors and specializes in shareholder rights litigation.

Staying Informed

For those affected by the developments surrounding Capricor Therapeutics, timely action is crucial. As the litigation progresses, updates will be essential for shareholders aiming to understand their rights and potential recovery options. Investors are urged to keep abreast not just of the lawsuit developments but also of ongoing communications from the company, particularly as new information unfolds.

In conclusion, the class action lawsuit against Capricor Therapeutics embodies the broader effort to hold corporations accountable for transparency and honesty in their communications with investors. As lawsuits like this unfold, they underscore the importance of vigilance in the financial marketplace, reminding shareholders to take proactive steps when they suspect wrongdoing by firms they invest in.